Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Lafutidine
Cat. No.:
OB0225LY-0158
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
Lafutidine is a new type of gastric mucous membrane protector with the properties of antacid and promoting gastric mucous membrane repair.
Synonym:
FRG-8813; 118288-08-7; rac Lafutidine; FRG-8813; (Z)-Lafutidine; Acetamide, 2-[(2-furanylmethyl)sulfinyl]-N-[(2Z)-4-[[4-(1-piperidinylmethyl)-2-pyridinyl]oxy]-2-buten-1-yl]-; 2-(Furan-2-ylmethylsulfinyl)-N-[(Z)-4-[4-(piperidin-1-ylmethyl)pyridin-2-yl]oxybut-2-enyl]acetamide
CAS No.:
118288-08-7
Compound CID:
5282136
Formula:
C22H29N3O4S
Formula Weight:
431.55
Specification
Relative Density:
1.252 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Lafutidine can be used to study the mechanisms involved in gastrointestinal diseases or play an important role in gastrointestinal drug development.
Library Information
Targets:
Histamine receptor family; 5-HT receptor family
Receptors:
H2 receptor
Pathways:
Neuronal signaling; Immunology/Inflammation; GPCR/G protein
Plate Number:
AOCL-2
Plate Location:
h11
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
80 mg/mL; 185.4 mM
Water Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
Ethanol Max Solubility:
11 mg/mL; 25.5 mM
